Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992073257> ?p ?o ?g. }
- W1992073257 endingPage "2699" @default.
- W1992073257 startingPage "2688" @default.
- W1992073257 abstract "c-MYC copy number gain (c-MYC gain) has been associated with aggressive behaviour in several cancers. However, the role of c-MYC gain has not yet been determined in lung adenocarcinomas classified by genetic alterations in epidermal growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase (ALK) genes. We investigated the clinicopathologic and prognostic significance of c-MYC gain for disease-free survival (DFS) and overall survival (OS) according to EGFR, KRAS, and ALK gene status and stages in lung adenocarcinomas.In 255 adenocarcinomas resected in Seoul National University Bundang Hospital from 2003 to 2009, fluorescence in situ hybridisation (FISH) with c-MYC probe and centromeric enumeration probe 8 (CEP8) was analysed using tissue microarray containing single representative core per each case. EGFR (codon 18 to 21) and KRAS (codon 12, 13, and 61) mutations were analysed by polymerase chain reaction and direct sequencing method from formalin-fixed, paraffin-embedded tissue sections. ALK rearrangement was determined by FISH method. c-MYC gain was defined as >2 copies per nucleus, chromosome 8 gain as ⩾3 copies per nucleus, and gain of c-MYC:CEP8 ratio (hereafter, c-MYC amplification) as ⩾2.We observed c-MYC gain in 20% (51 out of 255), chromosome 8 gain in 5.5% (14 out of 255), c-MYC amplification in 2.4% (6 out of 255), EGFR mutation in 49.4% (118 out of 239), KRAS mutation in 5.7% (7 out of 123), and ALK rearrangement in 4.9% (10 out of 205) of lung adenocarcinomas. c-MYC gain was observed in 19% (22 out of 118) of patients with lung adenocarcinomas with an EGFR mutation, but not in any patients with a KRAS mutation, or an ALK rearrangement. c-MYC gain (but not chromosome 8 gain or c-MYC amplification) was an independent poor-prognostic factor in the full cohort of lung adenocarcinoma (P=0.022, hazard ratio (HR)=1.71, 95% confidence interval (CI), 1.08-2.69 for DFS; P=0.032, HR=2.04, 95% CI, 1.06-3.91 for OS), as well as in stage I subgroup (P=0.023, HR=4.70, 95% CI, 1.24-17.78 for DFS; P=0.031, HR=4.65, 95% CI, 1.15-18.81 for OS), and in EGFR-mutant subgroup (P=0.022; HR=2.14; 95% CI, 1.11-4.10 for DFS).c-MYC gain (but not chromosome 8 gain or c-MYC amplification) was an independent poor-prognostic factor for DFS and OS in lung adenocarcinomas, both in full cohort and stage I cancer, and possibly for DFS in EGFR-mutant adenocarcinomas. Additional studies are required to determine if patients with lung adenocarcinoma with c-MYC gain are candidates for additional first-line treatment to mitigate their increased risk for disease progression and death." @default.
- W1992073257 created "2016-06-24" @default.
- W1992073257 creator A5011576110 @default.
- W1992073257 creator A5013601337 @default.
- W1992073257 creator A5019496865 @default.
- W1992073257 creator A5024591723 @default.
- W1992073257 creator A5024696731 @default.
- W1992073257 creator A5027378972 @default.
- W1992073257 creator A5029089458 @default.
- W1992073257 creator A5069856775 @default.
- W1992073257 creator A5080559983 @default.
- W1992073257 creator A5083980357 @default.
- W1992073257 date "2014-05-01" @default.
- W1992073257 modified "2023-10-15" @default.
- W1992073257 title "Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas" @default.
- W1992073257 cites W1250565189 @default.
- W1992073257 cites W1483045085 @default.
- W1992073257 cites W1974619802 @default.
- W1992073257 cites W1987431581 @default.
- W1992073257 cites W1988284275 @default.
- W1992073257 cites W1995401663 @default.
- W1992073257 cites W1995427420 @default.
- W1992073257 cites W2010561682 @default.
- W1992073257 cites W2011419722 @default.
- W1992073257 cites W2018319486 @default.
- W1992073257 cites W2021481801 @default.
- W1992073257 cites W2021536610 @default.
- W1992073257 cites W2026234244 @default.
- W1992073257 cites W2033384486 @default.
- W1992073257 cites W2036434511 @default.
- W1992073257 cites W2042386784 @default.
- W1992073257 cites W2046015115 @default.
- W1992073257 cites W2050968466 @default.
- W1992073257 cites W2056120923 @default.
- W1992073257 cites W2056559464 @default.
- W1992073257 cites W2059078891 @default.
- W1992073257 cites W2064477878 @default.
- W1992073257 cites W2065437747 @default.
- W1992073257 cites W2071324577 @default.
- W1992073257 cites W2075321890 @default.
- W1992073257 cites W2077194843 @default.
- W1992073257 cites W2082030035 @default.
- W1992073257 cites W2083252919 @default.
- W1992073257 cites W2084748434 @default.
- W1992073257 cites W2091453323 @default.
- W1992073257 cites W2098924171 @default.
- W1992073257 cites W2103299429 @default.
- W1992073257 cites W2105061544 @default.
- W1992073257 cites W2108192088 @default.
- W1992073257 cites W2115111607 @default.
- W1992073257 cites W2117649404 @default.
- W1992073257 cites W2126410372 @default.
- W1992073257 cites W2131339364 @default.
- W1992073257 cites W2133000857 @default.
- W1992073257 cites W2139631289 @default.
- W1992073257 cites W2156440831 @default.
- W1992073257 cites W2156660543 @default.
- W1992073257 cites W2157328259 @default.
- W1992073257 cites W2158734599 @default.
- W1992073257 cites W2159393668 @default.
- W1992073257 cites W2161577298 @default.
- W1992073257 cites W2162461165 @default.
- W1992073257 cites W2163149604 @default.
- W1992073257 cites W2128696591 @default.
- W1992073257 doi "https://doi.org/10.1038/bjc.2014.218" @default.
- W1992073257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4037828" @default.
- W1992073257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24809777" @default.
- W1992073257 hasPublicationYear "2014" @default.
- W1992073257 type Work @default.
- W1992073257 sameAs 1992073257 @default.
- W1992073257 citedByCount "57" @default.
- W1992073257 countsByYear W19920732572014 @default.
- W1992073257 countsByYear W19920732572015 @default.
- W1992073257 countsByYear W19920732572016 @default.
- W1992073257 countsByYear W19920732572017 @default.
- W1992073257 countsByYear W19920732572018 @default.
- W1992073257 countsByYear W19920732572019 @default.
- W1992073257 countsByYear W19920732572020 @default.
- W1992073257 countsByYear W19920732572021 @default.
- W1992073257 countsByYear W19920732572022 @default.
- W1992073257 countsByYear W19920732572023 @default.
- W1992073257 crossrefType "journal-article" @default.
- W1992073257 hasAuthorship W1992073257A5011576110 @default.
- W1992073257 hasAuthorship W1992073257A5013601337 @default.
- W1992073257 hasAuthorship W1992073257A5019496865 @default.
- W1992073257 hasAuthorship W1992073257A5024591723 @default.
- W1992073257 hasAuthorship W1992073257A5024696731 @default.
- W1992073257 hasAuthorship W1992073257A5027378972 @default.
- W1992073257 hasAuthorship W1992073257A5029089458 @default.
- W1992073257 hasAuthorship W1992073257A5069856775 @default.
- W1992073257 hasAuthorship W1992073257A5080559983 @default.
- W1992073257 hasAuthorship W1992073257A5083980357 @default.
- W1992073257 hasBestOaLocation W19920732571 @default.
- W1992073257 hasConcept C104317684 @default.
- W1992073257 hasConcept C117643217 @default.
- W1992073257 hasConcept C120821319 @default.
- W1992073257 hasConcept C121608353 @default.
- W1992073257 hasConcept C141231307 @default.